Rigid gas permeable lens highly influences the interpretation of CXL results

Article

Wearing a rigid gas permeable lens can lead to improved topographic parameters and can significantly alter a number of study parameters.

Wearing a rigid gas permeable lens can lead to improved topographic parameters and can significantly alter a number of study parameters, claims a paper published in the British Journal of Ophthalmology.

A prospective, non-comparative study led by Dr Koppen Carina, Department of Ophthalmology, Antwerp University Hospital, Belgium, comprised of 15 eyes without rigid gas permeable contact lens (CL) and 12 eyes fitted with a CL from 1 to 10 weeks after ultraviolet A/riboflavin cross-linking (CXL) for the stabilisation of progressive keratoconus.

Refractive sphere and cylinder, maximal keratometry value (K max), simulated keratometry steep, flat, astigmatism, refractive power (RP) steep, flat and astigmatism, I-S value on EyeSys, K max on Pentacam and change from baseline of best spectacle-corrected visual acuity (BSCVA) were all used to measure the effect of CXL treatment on patients. The results of the study were recorded pre-CXL and in 6 month intervals for 18 months post-CXL.

There were no study parameters that demonstrated a significant change from baseline results in eyes without CL.

However, in eyes fitted with CL post-CXL I-S value and K max on EyeSys at all time intervals, RP steep and simulated astigmatism at 6 and 12 months and RP flat at 12 months all showed significant improvement.

CL can greatly influence the interpretation of CXL results, with lens wear improving topographic parameters.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.